Health
Antibiotice Iasi Posts 0.5% Higher Sales Revenue And Flat Profit In 2014
Romanian state-run drugmaker Antibiotice Iasi (ATB.RO) on Friday said its sales revenue inched up 0.5% on the year in 2014, to 318.9 million lei (EUR71.8 million), while its profit stagnated...
Medsana Scraps Unprofitable Subscription Accounts, Switches To Individuals And Insurance
Medsana, the first foreign investment on Romania’s healthcare market, reduced the weight of subscriptions in revenue to 33% in 2014 from 40% in the previous year as it deliberately renounced...
Biofarm Sales Rose 9.5% Last Year, To RON128.9M
Sales of pharmaceutical manufacturer Biofarm (BIO.RO) rose 9.5% last year, to RON128.9 million (around EUR29.1 million), while the company's net profit grew 2%, to RON26.1 million (EUR5.9 mi...
Farmaceutica Remedia Sales Grew 4.3% In 2014, To RON244.7M
Pharmaceutical wholesaler Farmaceutica Remedia Deva (RMAH.RO) had net sales of RON244.68 million (EUR55 million) in 2014, up 4.3% on the year, and its net profit rose 3.6%, to RON3.12 millio...
Labormed Wants Drugs Cheaper Than RON10 Off Reimbursed List Over Clawback Tax
Generics producer Labormed, part of Alvogen, is reassessing its medicines portfolio until March to remove products cheaper than RON10 from the reimbursed medicines list, as its sales rose 2%...
Gedeon Richter Sales In Romania Down 3.3% In 2014, To EUR144M
Sales of Hungarian pharmaceutical group Gedeon Richter in Romania fell 3.3% on the year in 2014, to EUR144 million, the group said in a report Monday.
Value4Capital Getting Ready To Exit MedLife
Private equity firm Value4Capital (V4C), which bought into private medical service operator MedLife in a EUR20 million deal in 2009, is getting ready to sell its 36% stake.
Pharma Retail In Romania: Over 8,200 Pharmacies Sharing EUR2.4B Market
Pharmaceutical retail in Romania, represented by more than 8,200 pharmacies, grew 1.7% on the year in 2014, to RON10.5 billion (EUR2.4 billion), according to estimates of market research com...
Sanofi Romania Set To Launch Four New Products In 2015
The non-prescription drug (OTC) market rose by over 10% last year, but the average annual growth pace will go down to 4-5% as people’s incomes are not expected to register significant increa...